DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C

Kandemir, Özlem; Gultekin, Onur

DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C

Onur GÜLTEKİN, (Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları AD, Mersin Üniversitesi Tıp Fakültesi, Mersin)

Özlem KANDEMİR (Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları AD, Mersin Üniversitesi Tıp Fakültesi, Mersin)

Türkiye Klinikleri Tıp Bilimleri Dergisi

3 1

Yıl: 2017 Cilt: 37 Sayı: 1 Sayfa Aralığı: 21 - 26 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C

Öz:

Amaç: Hepatit C virüsü çeşitli yollarla bulaşabilmesine rağmen, gerek tüm dünyada gerekse belli bölgelerde HCV enfeksiyonunun yayılmasında rol oynayan en önemli risk faktörü damar içi uyuşturucu madde kullanıcılarıdır (DİUMK).Ülkemizde HCV ile kronik enfekte DİUMK'larda yapılmış çalışma sayısı oldukça kısıtlıdır. Bu çalışmada kronik HCV enfeksiyonlu damar içi uyu- şturucu madde kullanıcılarında HCV genotiplerinin dağılımını saptamak amaçlanmıştır. Gereç ve Yöntemler: Çalışma grubuna Mersin Ünivesitesi Tıp Fakültesi, Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları bölümüne başvuran HCV ile enfekte DİUMK'lar dahil edildi. Serolojik testler ELİSA yöntemi ile çalışıldı. HCV enfeksiyonu HCV RNA saptanması ile doğrulandı. HCV RNA izolasyonundan (MagNA Pure LC Total Nucleic Acid Isolation Kit, Roche) sonra, viral yük tayini COBAS TaqMan 48 (Roche Diagnostic, ABD) prosedürüne göre "real time" polimeraz zincir reaksiyonu (RT-PCR) tekniği ile gerçekleştirildi. HCV genotiplerinin belirlenmesi, AMPLIQUALITY HCV-TS (AB Analitica) test kiti yöntemi kullanılarak yapıldı. Bulgular: Kronik HCV enfeksiyonlu 238 DİUMK'nın 120'sinin (%50,4) genotip 1 ile enfekte olduğu gözlendi. Bunların112'si (%93,3) subtip1a ve 8'i (%6,7) subtip 1b ile enfekteydi. Genotip 3, olguların 81'inde (bütün olguların %34'ü), genotip 2, 22'sinde (bütün olguların %9,3'ü) ve genotip 4, olguların 15'inde (bütün olguların %6,3'ü) saptandı. Genotip 5 ve 6'ya çalışma grubunda rastlanmadı. Çalışmada HCV genotipi ve hastaların yaşı ve serum HCV RNA düzeyleri arasında bir ilişki saptanmadı. Sonuç: Çalışmamızda genotip subtip 1a ve genotip 3'ün bu zor hasta grubunda egemen genotip olduğu gösterilmiştir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Kronik Hepatit C Enfeksiyonlu Damar İçi Uyuşturucu Madde Kullanıcılarında Hepatit C Virüs Genotiplerinin Dağılımı

Öz:

Objective: Although there are many route for HCV transmission, currently the major contributor and driving risk factor for localized and universal spreading of HCV infection are injection drug users (IDUs). In our country the number of studies concerning IDUs with chronic hepatitis C is very scantly. In this study we aimed to determine the distribution of various genotypes of HCV in IDUs with chronic HCV infection. Material and Methods: The study group included IDUs recruited at Mersin University, department of Clinical Microbiology and Infectious Diseases. Serological tests were done ELISA method. HCV infection was confirmed by presence of HCV RNA. After the HCV-RNA isolation (MagNA Pure LC Total Nucleic Acid Isolation Kit, Roche), viral load was determined according to COBAS TaqMan 48 (Roche Diagnostic, ABD) procedure. This was performed with “real time” polymerase chain reaction (RT-PCR) technique. HCV genotypes were studied by AMPLIQUALITY HCV-TS (AB Analitica) kits Results: Genotype 1 was observed in 120 of the 238 IDUs (50.4%) with chronic HCV infection. Of these, 112 IDUs showed infection with subtype 1a (93.3%) and 8 with subtype 1b (6.7%). Genotype 3 was determined in 81 IDUs (34% of all cases), genotype 2 in 22 (9.3% of all cases), and genotype 4 in 15 IDUs (6.3% of all cases). Genotypes 5 and 6 were not found in the study population. There was no association of HCV genotype with patient age and serum HCV RNA levels. Conclusion: This study demonstrated that genotype subtype 1a and genotype 3 are predominant genotypes in our troublesome population

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Zanini B, Benini F, Pigozzi MG, Furba P, Giacò E, Cinquegrana A, et al. Addicts with chronic hepatitis C: difficult to reach, manage or treat? World J Gastroenterol 2013;19(44):8011-9.
2. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010;32(13): 2117-38.
3. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43(1): 66-72.
4. Barut HŞ, Günal Ö. [Global and National Epidemiology of Hepatitis C]. Klimik Dergisi 2009;22(2):38-43.
5. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001;345(3):215-7.
6. Gigi E, Sinakos E, Lalla T, Vrettou E, Orphanou E, Raptopoulou M. Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. Hippokratia 2007;11(4):196-8.
7. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virüs infection and injection drug users: prevention, risk factors and treatment. Clin Infect Dis 2005;(40 Suppl 5):S330-5.
8. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378(9791): 571-83.
9. Mousavi SF, Moosavy SH, Alavian SM, Eghbali H, Mahboobi H. Distribution of hepatitis C virus genotypes among patients with hepatitis C virus infection in hormozgan, Iran. Hepat Mon 2013;13(12):e14324- 9.
10. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19(1):13-8.
11. Westin J, Lindh M, Lagging LM, Norkrans G, Westjål R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999;31(4):355- 8.
12. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994;32(4):884- 92.
13. Cha TA, Beall E, Irvine B, Kolberg J, Chien D, Kuo G, et al. At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci 1992;89(15):7144-8.
14. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 2005;75(4):538- 49.
15. Oztürk AB, Doğan UB, Oztürk NA, Ozyazici G, Demir M, Akin MS, et al. Hepatitis C virus genotypes in Adana and Antakya regions of Turkey. Turk J Med Sci 2014;44(4):661-5.
16. Caliskan A, Kirisci O, Ozkaya E, Ozden S, Tumer S, Caglar S, et al. Distribution and predominance of genotype 3 in hepatitis C virus carriers in the province of Kahramanmaras, Turkey. Hepat Mon 2015;15(4): e25142-9.
17. Kayman T, Karakükçü Ç, Karaman A, Gözütok F. [Genotypic distribution of hepatitis C virus infection in Kayseri Region]. Turk Microbiol Soc 2012;42(2):21- 6.
18. Andalibalshohada A, Rezaei SA, Abedi F. HCV prevalence and predominant genotype in IV drug users. Rev Clin Med 2014;1(4):200-6.
19. Krekulova L, Rehak V, Madrigal N, Johnson M, Killoran P, Riley LW. Genotypic and epidemiologic characteristics of hepati¬tis C virus infections among recent injection drug user and nonuser populations. Clin Infect Dis 2001;33(8):1435- 8.
20. Chlabicz S, Flisiak R, Kowalczuk O, Wiercińska-Drapalo A, Pytel-Krolczuk B, Prokopowicz D, et al. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland. J Med Virol 2008;80(4):615- 8.
21. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(3 Suppl 1):122S7S.
22. Mıstık R. [Epidemiology of hepatitis C virüs infection]. Tabak F, Tosun S, editörler. Viral Hepatit Kitabı. 1. Baskı. İstanbul: Viral Hepatitle Savaşım Derneği Yayını, İstanbul Tıp Kitabevi; 2013. p.83- 112.
23. Çekin Y, Gür N, Çekin AH, Altuğlu İ, Yazan Sertöz R. [Investigation of hepatitis C virüs genotype distribution in patients with chronic hepatitis C infections in Antalya Training and Research Hospital, Turkey]. Mikrobiol Bul 2014;48(3):484- 90.
24. Tezcan S, Ulger M, Aslan G, Yaraş S, Altıntaş E, Sezgin O, et al. [Determination of hepatitis C virus genotype distribution in Mersin province, Turkey]. Mikrobiyol Bul 2013; 47(2):332-8.
25. Bourlière M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002;9(1):62-70.
26. Micalessi MI, Gérard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. J Med Virol 2008;80(4):640- 5.
27. Du H, Qi Y, Hao F, Huang Y, Mao L, Ji S, et al. Complex patterns of HCV epidemic in Suzhou: evidence for dual infection and HCV recombination in East China. J Clin Virol 2012;54(3):207-12.
28. Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virüs epidemic among injecting drug users. Infect Genet Evol 2005;5(2):131-9.
29. Zhang Z, Yao Y, Wu W, Feng R, Wu Z, Cun W, et al. Hepatitis C virus genotype diversity among intravenous drug users in Yunan Province, Southwestern China. PLoS One 2013;8(12):e82598.
30. Üçbilek E, Abayli B, Koyuncu MB, Midikli D, Gözüküçük S, Akdağ A, et al. Distribution of hepatitis C virus genotypes among intravenous drug useres in the Çukurova region of Turkey. Turk J Med Sci 2016;46(1):66- 71.
31. Schröter M, Zöllner B, Schäfer P, Reimer A, Müller M, Laufs R, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002;40(5):1866- 8.
32. Chlabicz S, Flisiak R, Kowalczuk O, Wiercińska-Drapalo A, Pytel-Krolczuk B, Prokopowicz D, et al. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland. J Med Virol 2008;80(4):615-8.

APA	Gultekin O, Kandemir Ö (2017). DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. , 21 - 26.
Chicago	Gultekin Onur,Kandemir Özlem DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. (2017): 21 - 26.
MLA	Gultekin Onur,Kandemir Özlem DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. , 2017, ss.21 - 26.
AMA	Gultekin O,Kandemir Ö DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. . 2017; 21 - 26.
Vancouver	Gultekin O,Kandemir Ö DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. . 2017; 21 - 26.
IEEE	Gultekin O,Kandemir Ö "DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C." , ss.21 - 26, 2017.
ISNAD	Gultekin, Onur - Kandemir, Özlem. "DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C". (2017), 21-26.

APA	Gultekin O, Kandemir Ö (2017). DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. Türkiye Klinikleri Tıp Bilimleri Dergisi, 37(1), 21 - 26.
Chicago	Gultekin Onur,Kandemir Özlem DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. Türkiye Klinikleri Tıp Bilimleri Dergisi 37, no.1 (2017): 21 - 26.
MLA	Gultekin Onur,Kandemir Özlem DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. Türkiye Klinikleri Tıp Bilimleri Dergisi, vol.37, no.1, 2017, ss.21 - 26.
AMA	Gultekin O,Kandemir Ö DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2017; 37(1): 21 - 26.
Vancouver	Gultekin O,Kandemir Ö DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2017; 37(1): 21 - 26.
IEEE	Gultekin O,Kandemir Ö "DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C." Türkiye Klinikleri Tıp Bilimleri Dergisi, 37, ss.21 - 26, 2017.
ISNAD	Gultekin, Onur - Kandemir, Özlem. "DİSTRİBUTİON OF HEPATİTİS C VİRUS GENOTYPES İN İNJECTİON DRUG USERS WİTH CHRONİC HEPATİTİS C". Türkiye Klinikleri Tıp Bilimleri Dergisi 37/1 (2017), 21-26.